ライフサイエンスコーパス: PF

1 PF and PA were measured with a Chair Stand Test, the REG

2 PF associated with higher scores in phonemic and semanti

3 PF lesions demonstrated homogenous fibrosis without epic

4 PF terminals were significantly larger in both lobules o

5 PF(HD) and radiofrequency lesions were delivered in 4 an

6 PF(HD) sections had higher transmurality rates than PF(L

7 PF-05089771 is an aryl sulfonamide Nav1.7 channel blocke

8 PF-06684511 was identified as a candidate PET ligand for

9 PF-06700841 improves clinical symptoms of chronic plaque

10 PF-06700841 was generally effective and well tolerated i

11 PF-06869206 had no effect on Npt2a-null mice, but promot

12 PF-5190457 (100 mg b.i.d.) reduced alcohol craving durin

13 PF-AES were clinically noninferior to PP-ZES (risk diffe

14 PF-AES were noninferior to PP-ZES regarding target-lesio

15 PF-PC LTP is associated with an increase in the size of

16 scores (difference: GPH = -5.1, GMH = -5.1, PF = -7.9; all P < 0.001).

17 s to mutant cells that have less PF (4 +/- 2 PF per cell tip) and fail to form a flat-ribbon, indicat

18 s proven to be general, as R(3) PF(2) , R(2) PF(3) , and RPF(4) compounds (as well as various cations

19 [Co(Py3Me-Bpy)(OH(2) )](PF(6) )(2) catalyzes the electrolytic HER at -1.3 V (vs.

20 to [Dy(III) (L(N6) )(2,4-di-(t) Bu-PhO)(2) ](PF(6) ) (1), [Dy(III) (L(N6) )(Ph(3) SiO)(2) ](PF(6) ) (

21 (6) ) (1), [Dy(III) (L(N6) )(Ph(3) SiO)(2) ](PF(6) ) (2) and [Dy(III) (L(N6) )(Ph(3) SiO)(2) ](BPh(4)

22 le-molecule magnet [Dy(Tp(py))F(pyridine)(2)]PF(6).

23 In addition, mer-[V(ddpd)(2)][PF(6)](3) shows very strong blue fluorescence with 2% qu

24 t the vanadium(III) complex mer-[V(ddpd)(2)][PF(6)](3) yielding phosphorescence around 1100 nm in val

25 2 RF+PF/8 PF), 34 left atrium roof (12 RF/22 PF), and 44 cavotricuspid isthmus (36 RF/8 PF) lines, wi

26 23 (PF-07059013) has advanced to phase 1 clinical trials.

27 thermal injury in 2 of 36 RF/PF and 0 of 24 PF/PF patients.

28 F and radiofrequency focal ablation, and (3) PF delivered directly atop the esophagus.

29 e reaction has proven to be general, as R(3) PF(2) , R(2) PF(3) , and RPF(4) compounds (as well as va

30 ategy by utilizing [(C(5) H(5) )Ru(NCMe)(3) ]PF(6) as a precatalyst for the disrotatory 6pai electroc

31 -hydroxy-1,4-naphthoquinone using Ru(bpy)(3)(PF(6))(2) as a photocatalyst under blue LED light irradi

32 g Crabtree's catalyst ([(COD)Ir(py)(PCy(3))][PF(6)], COD = 1,5-cyclooctadiene, py = pyridine, Cy = cy

33 s with PyAOP ([(H(8)C(4)N)(3)PON(4)C(5)H(3)][PF(6)]) to yield an activated TriMP, [P(3)O(9)P(NC(4)H(8

34 Preclinical experiments reveal 4 (PF-00835231) as a potent inhibitor of CoV-2 3CL(pro) wit

35 tion of H(MQ(+))H with O(NH)O in 0.1 M NBu(4)PF(6)/CD(2)Cl(2) gives a K(assoc) of 500 M(-1), typical

36 , upon two-electron reduction in 0.1 M NBu(4)PF(6)/CH(2)Cl(2), cyclic voltammetry studies indicate a

37 Durable isolation improved from 61.5% PF(LD) to 100% with PF(HD) (P=0.04), and all linear lesi

38 inations of anions ((PF(6))(-)/(AsF(6))(-), (PF(6))(-)/(SbF(6))(-), and (AsF(6))(-)/(SbF(6))(-)) was

39 Indeed, evolving 7 PF mutant strains in the presence of drug revealed 3 ada

40 and selective irreversible MAGL inhibitor 7 (PF-06809247) as a suitable radioligand lead, which upon

41 once-daily 30 mg (n = 14) or 100 mg (n = 7) PF-06700841 or placebo (n = 9) for 28 days.

42 r lesions included 14 mitral (4 RF/2 RF+PF/8 PF), 34 left atrium roof (12 RF/22 PF), and 44 cavotricu

43 2 PF), and 44 cavotricuspid isthmus (36 RF/8 PF) lines, with therapy duration times of 5.1+/-3.5, 1.8

44 A pathogen was identified in 12/14 (86%) PF specimens tested by either culture (9/14) or PCR (9/1

45 ow report the synthesis of the tetramic acid PF-1018 through an 8pai electrocyclization, the product

46 henomenon is not restricted to the activated PF synapses.

47 ould be a novel therapeutic approach against PF.

48 lity of the ghrelin receptor inverse agonist PF-5190457 when co-administered with alcohol.

49 (GLP-1) receptor by the non-peptide agonist PF 06882961 and GLP-1 that was not observed for another

50 r 30 mg) of a novel, selective D(1) agonist (PF-06412562).

51 of a novel ghrelin receptor inverse agonist, PF-5190457, when co-administered with alcohol.

52 h active LN from inactive disease are ALCAM, PF-4, properdin, and VCAM-1 among African-Americans, sE-

53 d quality of life scores were compared among PF quartiles and PA levels (low, moderate and high) with

54 In multivariable analysis, PF was not a statistically significant factor for OAS or

55 AmA, 6-azauridine, azaribine, and PF also showed potent inhibitory effect in pretreatment

56 he predominant pathogen identified in LA and PF, respectively.

57 imed to study the association between PA and PF with cognitive function and quality of life using cro

58 Prucalopride and PF-04995274 attenuated learned fear and decreased stress

59 mong Caucasians, and ALCAM, VCAM-1, TFPI and PF-4 among Asians.

60 ical setting, we analyzed AID expression and PFs in a CLL cohort before and during ibrutinib treatmen

61 oduct for the three combinations of anions ((PF(6))(-)/(AsF(6))(-), (PF(6))(-)/(SbF(6))(-), and (AsF(

62 Intriguingly, a few CIs, such as PF-3450074 (PF74) and GS-CA1, exhibit effects at multipl

63 MKII controls the direction of plasticity at PF-PC synapses, and demonstrates that the binding of fil

64 25 thoracic veins and create 5 right atrial (PF(LD)), 6 mitral (PF(HD)), and 6 roof lines (radiofrequ

65 he yellow polymorphs of [(C(6)H(11)NC)(2)Au](PF(6)) and [(C(6)H(11)NC)(2)Au](AsF(6)) contain single c

66 ng equimolar amounts of [(C(6)H(11)NC)(2)Au](PF(6)) and [(C(6)H(11)NC)(2)Au](AsF(6)).

67 as neither polymorph of [(C(6)H(11)NC)(2)Au](PF(6)) nor [(C(6)H(11)NC)(2)Au](SbF(6)) is thermochromic

68 .50)(AsF(6))(0.50), and [(C(6)H(11)NC)(2)Au](PF(6))(0.25)(AsF(6))(0.75) are vapochromic, whereas the

69 Mixed crystals such as [(C(6)H(11)NC)(2)Au](PF(6))(0.50)(AsF(6))(0.50) have been prepared by adding

70 ))(0.75)(AsF(6))(0.25), [(C(6)H(11)NC)(2)Au](PF(6))(0.50)(AsF(6))(0.50), and [(C(6)H(11)NC)(2)Au](PF(

71 the yellow crystals of [(C(6)H(11)NC)(2)Au](PF(6))(0.50)(SbF(6))(0.50) and [(C(6)H(11)NC)(2)Au](AsF(

72 colorless mixed crystal [(C(6)H(11)NC)(2)Au](PF(6))(0.50)(SbF(6))(0.50) is thermochromic and converts

73 The yellow crystals of [(C(6)H(11)NC)(2)Au](PF(6))(0.75)(AsF(6))(0.25), [(C(6)H(11)NC)(2)Au](PF(6))(

74 m a crystal of the type [(C(6)H(11)NC)(2)Au](PF(6))(n)(AsF(6))(1-n) from colorless (blue-emitting) to

75 high degree of ion-pair association between PF(6)(1-) and the metallocenium ion, resulting in a fast

76 stress were significantly different between PF and HS animals (P < 0.05).

77 le the beta1AR antagonist metoprolol blocked PF-PC LTP, which was also absent in Epac2 (-/-) mice.

78 Alcohol did not affect blood PF-5190457 concentrations.

79 e of alcohol sedative actions), and on blood PF-5190457 concentrations in rats.

80 Both PF and PA levels were strongly associated with a better

81 examining the state-dependent inhibition by PF-05089771 and lidocaine of human Nav1.7 channels expre

82 te under drug-free conditions, inhibition by PF-05089771 was both enhanced and speeded in the presenc

83 s led to the discovery of clinical candidate PF-05221304 (12), which selectively inhibits liver DNL i

84 the identification of the clinical candidate PF-06372865.

85 the identification of the clinical candidate PF-06826647 (22).

86 ovalent modulator of HbS, clinical candidate PF-07059013 (23).

87 We found that ibrutinib decreases the CLL PFs and, interestingly, also reduces AID expression, whi

88 isolation and linear ablation, (2) combined PF and radiofrequency focal ablation, and (3) PF deliver

89 l molecules including the drug-like compound PF-06446846 (PF846) selectively inhibit the synthesis of

90 .7 channels by the aryl sulfonamide compound PF-05089771, consistent with state-dependent binding by

91 d TRN cell-intrinsic mechanisms that control PF and oscillation frequency.SIGNIFICANCE STATEMENT Slow

92 cs to counteract stem cell exhaustion in DC, PF, and possibly other aging-related diseases.

93 is likely a crucial parameter in determining PF synaptic plasticity, and the occurrence of hyperpolar

94 d fields at low dose (PF(LD)) and high dose (PF(HD)) and followed for 4 and 2 weeks, respectively, to

95 were treated with pulsed fields at low dose (PF(LD)) and high dose (PF(HD)) and followed for 4 and 2

96 when compared with participants without DPN (PF, 33 msec vs 32 msec; P = .03).

97 l-catalytic system, with [Ir(ppy)(2)(dtbbpy)]PF(6) as a photosensitizer, NiBr(2).glyme as a precataly

98 o hazard ratio for 1-year graft loss at each PF value, which was standardized with graft weight.

99 genomic, PF-external mutations that elevate PF basal expression, possibly by affecting transcription

100 at lidocaine binding to the channel enhances PF-05089771 inhibition by altering the equilibrium betwe

101 e with radiofrequency energy) or an entirely PF approach.

102 Intrapelvic extra-PF disease was detected in 90% (9/10) by PSMA and in 31%

103 9% (6/31) and at sites outside the PF (extra-PF) in 8% (7/88), 19% (17/91), and 32% (10/31) by MRI, (

104 ate the regional brain distribution of (18)F-PF-06684511 in NHPs under baseline and blocking conditio

105 The effective dose of (18)F-PF-06684511 was 0.043 mSv/MBq for humans.

106 nally, the effective radiation dose of (18)F-PF-06684511 was estimated on the basis of the whole-body

107 nonhuman primate (NHP) PET study using (18)F-PF-06684511.

108 [(18)F]PF-NB1 binding was selective to GluN2B-rich forebrain re

109 N-N, A-N, and A-A to display power factors (PFs) of 3.2 muW m(-1) K(-2), 1.6 muW m(-1) K(-2), and 0.

110 den for their child on the EQ-5D-Y and FAQLQ-PF dependent upon PA severity.

111 ity of Life Questionnaire-Parent Form (FAQLQ-PF) and Food Allergy Independent Measure (FAIM).

112 8-12 years, and the FAQLQ-Parent Form (FAQLQ-PF) was administered to their parents at the start of OI

113 Here, we use a synthetic positive-feedback (PF) gene circuit integrated into haploid Saccharomyces c

114 ion or potentiation at their parallel fiber (PF) input.

115 ) input provides a signal to parallel fiber (PF) synapses, triggering PF synaptic plasticity.

116 calizes to the glutamatergic parallel fiber (PF) terminals of the cerebellar granule cells and partic

117 g-term potentiation (LTP) at parallel fiber (PF)-Purkinje cell (PC) synapses depends on a Ca(2+)-indu

118 l inversion of plasticity at parallel fibre (PF)-Purkinje cell (PC) synapses in cerebellar cortex.

119 s in the pathogenesis of pulmonary fibrosis (PF) and therapeutic potential of ER stress inhibition in

120 latives of patients with pulmonary fibrosis (PF) consented to participate in a screening study that i

121 Pulmonary fibrosis (PF) is a major public health problem with limited therap

122 del of bleomycin-induced pulmonary fibrosis (PF).

123 tosis congenita (DC) and pulmonary fibrosis (PF).

124 nary disease (COPD), and pulmonary fibrosis (PF).

125 ects most susceptible to pulmonary fibrosis (PF).

126 le between delivering biphasic pulsed field (PF) and radiofrequency energy from a 9-mm lattice-tip ca

127 ng plateau potentials and persistent firing (PF), and in turn, resulted in sustained synaptic inhibit

128 nput is delayed by 100-150 ms from the first PF input in both cases.

129 ecline in the elderly, but physical fitness (PF) could be a better predictor of cognitive function.

130 a burgdorferi has 7-11 periplasmic flagella (PF) that arise from the cell poles and extend toward the

131 in the upper and lower leg (plantar flexors [PF], 62% vs 78% vs 89%; P < .001; knee extensors [KE], 7

132 While portal flow (PF) plays an important role in determining graft outcome

133 trans-thoracic lung (LA) and pleural fluid (PF) aspiration was performed on a sample of pneumonia ca

134 ated (MF) analogs of (18)F-para-fluorinated (PF)-NB1, a 3-benzazepine-based radiofluorinated probe.

135 clinical feasibility and safety of (1) focal PF-based thoracic vein isolation and linear ablation, (2

136 The lattice-tip catheter can deliver focal PF to durably isolate veins and create linear lesions wi

137 Periodic focusing (PF)-drift tube (DT)-ion mobility (IM) provides first-pri

138 th an endemic focus for pemphigus foliaceus (PF), also known as Fogo Selvagem.

139 renergic receptors (betaARs) is required for PF-PC LTP, although noradrenergic varicosities are appos

140 Our findings suggest that screening for PF in relatives might be warranted.

141 presenting a high-affinity binding site for PF-05089771 and suggesting that combinations of agents t

142 structures reveal that the binding sites for PF 06882961 and GLP-1 substantially overlap, whereas CHU

143 ) was generally higher for TFAB(1-) than for PF(6)(1-) as the ions diffuse into the crystal bulk, due

144 ve-ground carbon stocks of a primary forest (PF), with cattle pasture containing just 3% of stocks re

145 ical prostatectomy (RP) fail prostate fossa (PF) salvage radiation treatment (SRT).

146 verexpressed in the proliferative fractions (PFs) of the malignant B lymphocytes, and its anomalous e

147 l correlations between pathologic fractures (PFs) and prognosis of patients with primary central high

148 Further, PF-670462 treatment produced a dose-dependent reduction

149 aled 3 adaptation scenarios through genomic, PF-external mutations that elevate PF basal expression,

150 o investigate the correlations between graft PF and graft outcomes in DDLT.

151 The other group (PF) was housed at 20 degrees C and pair-fed to match the

152 , n = 210, P = 0.011) and the high-PF group (PF >= 155 mL/min/100 g, n = 159, P = 0.018) showed signi

153 val compared with the intermediate-PF group (PF >= 65 mL/min/100 g and < 155 mL/min/100 g, n = 632).

154 The low-PF group (PF < 65 mL/min/100 g, n = 210, P = 0.011) and the high-P

155 H/PF/2013 and PRVABC59 differ by an additional 31 noncodin

156 nces but nucleotide sequences derived from H/PF/2013 or PRVABC59.

157 equency variant in PRVABC59 not present in H/PF/2013: a G-to-T change at nucleotide 1965 producing a

158 units (FFU) of ZIKV (n = 3 for FP isolate H/PF/2013; n = 3 for PR isolate PRVABC59) at midgestation

159 t to attenuate the PRVABC59 strain but not H/PF/2013.

160 The consensus sequences of H/PF/2013 and PRVABC59 differ by 3 amino acids, but these

161 We found that strain H/PF/2013 caused 100% lethality in Ifnar1(-/-) mice, where

162 otide differences in the 3' quarter of the H/PF/2013 genome were sufficient to confer virulence in If

163 tify a second virulence determinant in the H/PF/2013 strain, which is driven by the viral nucleotide

164 the cationic ruthenium hydride [Ru(tpy)bpy)H]PF(6) (tpy = 2,2':6',2"-terpyridine, bpy = 2,2'-bipyridi

165 = 18 years of age; 11.3% of all patients had PFs.

166 /min/100 g, n = 210, P = 0.011) and the high-PF group (PF >= 155 mL/min/100 g, n = 159, P = 0.018) sh

167 In contrast, the patients in the high-PF group had milder reperfusion injury, but had lower in

168 s; in the prefrontal cortex and hippocampus, PF-670462 also reduced plaque size.

169 Very little is known about how PF are assembled within the periplasm of spirochaetal ce

170 related to functional data to understand how PF 06882961, but not CHU-128, can closely mimic the phar

171 gh noradrenergic varicosities are apposed in PF-PC contacts.

172 urons, and are not synaptically connected in PF.

173 ress and resulting epithelial dysfunction in PF and suggest ER stress as a potential mechanism linkin

174 y demonstrated that betaARs are expressed in PF boutons.

175 l, octane and beta-damascenone were found in PF-H samples that could indicate more intensive oxidatio

176 ed in HS animals (P < 0.05) but increased in PF animals (P < 0.05) from period 1 to period 2.

177 apeutic potential of ER stress inhibition in PF.Methods: The role of ER stress in AEC dysfunction and

178 owever, whether Epac proteins participate in PF-PC LTP is not known.

179 ompounds from these patent series, including PF 06882961, are currently in clinical trials for treatm

180 ts were found in mice with bleomycin-induced PF.

181 and a mouse model of bleomycin (BLM)-induced PF.

182 dc5 mitigates the progression of BLM-induced PF and lung function deterioration.

183 The TYK2/Janus kinase 1 inhibitor PF-06700841 will directly suppress TYK2-dependent IL-12

184 human clinical trials with our ACC inhibitor PF-05175157 led to robust reduction of de novo lipogenes

185 he efficacy and safety of the FAAH-inhibitor PF-04457845 in reduction of cannabis withdrawal and cann

186 The NPT2a-selective small-molecule inhibitor PF-06869206 was previously shown to reduce phosphate upt

187 Blockade of S6K1 by a specific inhibitor PF-4708671 synergistically enhanced the efficacy of TKI

188 adults were randomized to an FAAH inhibitor (PF-04457845, 4 mg orally, once daily; n = 16) or placebo

189 discovery of a first-in-class KHK inhibitor, PF-06835919 (8), currently in phase 2 clinical trials.

190 istration of the selective kinase inhibitor, PF-360, attenuates neurodegeneration induced by G2019S L

191 itive to two PAK4 small-molecule inhibitors, PF-3758309 and KPT-9274, which elicited significant anti

192 raft survival compared with the intermediate-PF group (PF >= 65 mL/min/100 g and < 155 mL/min/100 g,

193 These results suggest that intraoperative PF plays an important role in determining early graft ou

194 BB0270 leads to mutant cells that have less PF (4 +/- 2 PF per cell tip) and fail to form a flat-rib

195 s to test if the population can restore lost PF function.

196 The low-PF group (PF < 65 mL/min/100 g, n = 210, P = 0.011) and

197 The patients in the low-PF group had severe reperfusion injury and were more fre

198 luorene, PF) to obtain a composite material (PF-TMPPCo), thereby achieving a homogeneous catalysis en

199 with 12.4+/-3.6 applications/vein with mean PF times of <90 seconds/vein.

200 enous boluses of PDE9-I (30, 100, and 300 mg PF-04749982 at 1-h intervals).

201 nd create 5 right atrial (PF(LD)), 6 mitral (PF(HD)), and 6 roof lines (radiofrequency+PF(HD)).

202 e of the capsid destabilising small molecule PF-74 also induced a cGAS-dependent IFN response.

203 biting this protease with the small-molecule PF-429242 blocks EBOV entry and infection.

204 und that the lateral interactions between MT PFs at the seam region were comparatively much weaker.

205 nflammatory pathology and fibrosis in murine PF, and may have clinical utility to treat human disease

206 a [Ir(eta(5):kappa(1)-C(5)Me(4)CH(2)py)(C,N)]PF(6), where C(5)Me(4)CH(2)py is 2-((2,3,4,5-tetramethyl

207 erence between bending angles of neighboring PFs tends to be larger compared with GTP ones.

208 ched Pt(111) facets (denoted as Pt(3.5 %) Ni PF) was obtained, showing prominent ORR activity with an

209 radiofrequency sections, as compared with no PF sections.

210 , prior activation of these betaARs occluded PF-PC LTP, while the beta1AR antagonist metoprolol block

211 In CKD rats, once-daily administration of PF-06869206 for 8 weeks induced an unabated acute phosph

212 in rodents and report that administration of PF-06869206 was well tolerated and elicited a dose-depen

213 and the anions being unsolvated (in case of PF(6) (-)) lowered ORR activation barriers with a 200-mV

214 ally and physiologically distinct classes of PF neurons that are also reciprocally connected with fun

215 F(6) is consumed, i.e., the concentration of PF(6)(-) is strongly decreasing.

216 cative of a role of BB0270 in the control of PF number and configuration.

217 mechanism for local coincident detection of PF-CF activity.

218 Both doses of PF-670462 lengthened the period and improved affect, whe

219 We tested the effects of PF-5190457 combined with alcohol on locomotor activity,

220 ion of Txndc5 markedly reduces the extent of PF and preserves lung function in mice following BLM tre

221 ypic assays to further explore the impact of PF on A. baumannii's microbial behavior and the strategi

222 cted as a classical competitive inhibitor of PF-3688 cleavage by Xase.

223 Potential PD markers of PF-5190457 were acyl-to-total ghrelin ratio and insulin-

224 a clear need to identify novel mediators of PF to develop effective therapeutics.

225 BACE1 occupancy of PF-06663195, estimated using the Lassen occupancy plot,

226 osteosarcomas, we observed the occurrence of PF to correlate with inferior OAS expectancies in adult

227 Adult patients surviving the acute phase of PF (exposed group) were matched 1:1 for age, sex, and Si

228 oles and controls the number and position of PF via regulating the flagellar protein stability and th

229 In the overall cohort, presence of PF correlated significantly with tumor site, histologic

230 iform LiF distribution from the reduction of PF(6) (-) ions.

231 ioral findings support continued research of PF-5190457 as a potential pharmacological agent to treat

232 a phase IIa study of efficacy and safety of PF-06700841, an oral TYK2/Jak1 inhibitor, in patients wi

233 ssociated Ca(2+) influx following a train of PF synaptic potentials in two cases: (1) when the dendri

234 nts undergoing either RF/PF (40 patients) or PF/PF (36 patients) ablation.

235 equency ablation or PFA anteriorly (RF/PF or PF/PF, respectively).

236 )-ketamine, Flx, RS-67,333, prucalopride, or PF-04995274 at varying doses, and then 1 week later were

237 linear Ca(2+) signals associated with paired PF-CF synaptic activity.

238 oundations adulterated with 90% of paraffin (PF-H) and compared to honey ripened in genuine beeswax (

239 PN than in DPN-negative and HC participants (PF, 20% vs 10% vs 8%; P < .001; KE, 13% vs 8% vs 6%; P <

240 with DPN when compared with HC participants (PF, 33 msec vs 31 msec; P < .001; KE, 32 msec vs 31 msec

241 In adult patients, PF remained an independent prognostic factor for OAS (P

242 mine how inhibition of MK2 by pharmacologic (PF-3644022) and genetic (siRNA) methods impacts tumor gr

243 the side chains of an ionomer (polyfluorene, PF) to obtain a composite material (PF-TMPPCo), thereby

244 t at 30 days, 90 days, and 1 year and PROMIS-PF-6b scores at 30 days, 90 days, 180 days, 270 days, an

245 Mean 6-minute walk distance, PROMIS-PF-6b, and PEmb-QOL scores improved over the course of 1

246 ractions between neighboring protofilaments (PFs) and less cooperative outward bending conformational

247 As a result, PtNi PF with enriched Pt(111) facets (denoted as Pt(3.5 %) Ni

248 rphology and expose Pt active facets in PtNi PFs.

249 [BRQ], 6-azauridine, azaribine, pyrazofurin [PF], AVN-944, mycophenolate mofetil [MMF], and mycopheno

250 In comparison, radiofrequency+PF(HD) sections revealed similar transmurality but expec

251 l (PF(HD)), and 6 roof lines (radiofrequency+PF(HD)).

252 In rats, PF-5190457 did not interact with the effects of alcohol

253 ants were randomly assigned (2:1) to receive PF-04457845 (4 mg per day) or placebo using a fixed bloc

254 rsus 46 (6.2%) of the 747 patients receiving PF-AES.

255 Linear lesions included 14 mitral (4 RF/2 RF+PF/8 PF), 34 left atrium roof (12 RF/22 PF), and 44 cavo

256 .6+/-8.3 min/patient, with a mean of 50.1 RF/PF lesions/patient.

257 d minor mucosal thermal injury in 2 of 36 RF/PF and 0 of 24 PF/PF patients.

258 adiofrequency ablation or PFA anteriorly (RF/PF or PF/PF, respectively).

259 rial fibrillation using either a combined RF/PF approach (capitalizing on the safety of PFA and the y

260 l fibrillation patients undergoing either RF/PF (40 patients) or PF/PF (36 patients) ablation.

261 There was no treatment effect on SF36-PF or any other QoL scores.

262 ss and SF36 Physical Functioning score (SF36-PF) at 26 weeks by intention to treat.

263 In vitro inflammation assays showed PF-271 reduced monocyte attachment and transmigration on

264 y our group, namely, Ru-sq ([Ru(DIP)(2)(sq)](PF(6)) (DIP, 4,7-diphenyl-1,10-phenanthroline; sq, semiq

265 ate against cancer, namely, [Ru(DIP)(2)(sq)](PF(6)) (Ru-sq) (DIP = 4,7-diphenyl-1,10-phenanthroline;

266 a was assessed with a tripeptidyl substrate (PF-3688).

267 and -oxo complexes, [Fe(V)(N)(MePy(2)tacn)](PF(6))(2) (3, MePy(2)tacn = methyl- N', N"-bis(2-picolyl

268 of the KE group was significantly lower than PF, despite being matched for energy provisions.

269 sections had higher transmurality rates than PF(LD) (98.3% versus 88.1%; P=0.03) despite greater mean

270 We concluded that PF, but not PA, is associated with a better cognitive fu

271 We observed that PF triggered differential expression of genes associated

272 However, we also reported that PF can increase glucose metabolism even in the absence o

273 Time course experiments revealed that PF induces AMP-activated protein kinase (AMPK) activatio

274 The PF lesions did not damage the phrenic nerve, vessels, an

275 The PF terminals in lobule V of CB (1) -KO contained less sy

276 pression (LTD) and potentiation (LTP) at the PF-PC synapse.

277 ever, whether ultrastructural changes at the PF-Purkinje cell (PC) synapses occur in CB (1) -KO remai

278 of endogenous Ca(2+) buffers produced by the PF-associated Ca(2+) influx via the mGluR1-mediated nons

279 rs with a 200-mV lower overpotential for the PF(6) (-) and ClO(4) (-) electrolytes compared with OTf(

280 The binding of the PF(6)(-) anion generates a 2:1 sandwich complex with blu

281 s on the ultrastructural architecture of the PF-PC synapses located in cerebellar lobules that differ

282 91), and 19% (6/31) and at sites outside the PF (extra-PF) in 8% (7/88), 19% (17/91), and 32% (10/31)

283 synaptic potential and colocalized with the PF Ca(2+) influx, occurring only when PF activity preced

284 This recurrence was found within the PF in 21.5% (19/88), 13% (12/91), and 19% (6/31) and at

285 ctively, when doped with N-DMBI, whereby the PFs recorded for N-N and A-N are among the highest repor

286 crease in the size of the RRP contributes to PF-PC LTP.SIGNIFICANCE STATEMENT G-protein-coupled recep

287 Patients were randomized to PF-06700841 30 mg once daily (QD), 60 mg QD, or placebo

288 ure containing just 3% of stocks relative to PFs.

289 to parallel fiber (PF) synapses, triggering PF synaptic plasticity.

290 Here we use PF-06840003 (IPD), a hIDO1-selective inhibitor in clinic

291 increased in the order of Fe < Ru < Os using PF(6)(1-) as the counteranion in all the stages of the v

292 th the PF Ca(2+) influx, occurring only when PF activity precedes the CF input.

293 ory gene and cellular pathways through which PF-06700841 improves the clinical manifestations of psor

294 tion improved from 61.5% PF(LD) to 100% with PF(HD) (P=0.04), and all linear lesions were successfull

295 lder first-degree relatives of patients with PF.

296 -controlled, within-subject human study with PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.

297 of TD, 84% of PD and 96% of FD found within PFs.

298 lts, 5-year OAS in patients with and without PF was 46% versus 69% (P < .001), and 5-year EFS was 36%

299 survival (OAS) of patients with and without PF was 63% versus 71%, respectively (P = .007), and 5-ye

300 nificantly between patients with and without PF.